PDF(Pubmed)
Abstract：
In the non-small-cell lung cancer (NSCLC) subtype, adenocarcinoma is the most common histology. The choice of first-line treatment depends on the mutational status. We present a case of a 54-year-old non-smoker woman with lung adenocarcinoma and extensive metastatic disease at diagnosis. The genetic analysis demonstrated a sensitizing epidermal growth factor receptor (EGFR) exon 19 mutation and she began treatment with a first-generation EGFR tyrosine kinase inhibitor (TKI), erlotinib. Due to successively acquired resistances and disease progression, six treatment lines were pursued, including third-generation EGFR TKI and chemotherapy. The patient accomplished an overall survival of 47 months. This case emphasized the importance of monitoring tumor mutational alterations, allowing us to implement a multi-line treatment. Targeted therapy in advanced NSCLC largely improved the overall survival of these patients.
摘要：
在非小细胞肺癌（NSCLC）亚型中，腺癌是最常见的组织学。一线治疗的选择取决于突变状态。我们介绍了一名54岁的非吸烟者女性，在诊断时患有肺腺癌和广泛的转移性疾病。遗传分析表明，表皮生长因子受体（EGFR）外显子19突变致敏，她开始使用第一代EGFR酪氨酸激酶抑制剂（TKI）进行治疗。厄洛替尼.由于相继获得的耐药性和疾病进展，沿用了六条治疗线，包括第三代EGFRTKI和化疗。患者的总生存期为47个月。该病例强调了监测肿瘤突变改变的重要性，允许我们实施多线治疗。晚期NSCLC的靶向治疗在很大程度上改善了这些患者的总体生存率。
